LONDON: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on treating iron deficiency with its lead product Accrufer/Feraccru (ferric maltol), announces that KYE Pharmaceuticals Inc. (‘KYE’) has submitted a New Drug Submission (‘NDS’) to Health Canada for the regulatory review and approval of Accrufer, for treatment of iron deficiency. If…